Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Research & Development (2016 - 2025)

Historic Research & Development for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $15.0 million.

  • Altimmune's Research & Development fell 2445.59% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.8 million, marking a year-over-year decrease of 1455.5%. This contributed to the annual value of $82.2 million for FY2024, which is 2496.54% up from last year.
  • Altimmune's Research & Development amounted to $15.0 million in Q3 2025, which was down 2445.59% from $17.2 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Research & Development ranged from a high of $29.2 million in Q3 2021 and a low of $11.9 million during Q1 2021
  • Over the past 5 years, Altimmune's median Research & Development value was $17.2 million (recorded in 2023), while the average stood at $18.0 million.
  • In the last 5 years, Altimmune's Research & Development surged by 12551.63% in 2021 and then tumbled by 3062.38% in 2022.
  • Over the past 5 years, Altimmune's Research & Development (Quarter) stood at $20.2 million in 2021, then fell by 4.98% to $19.2 million in 2022, then fell by 11.84% to $16.9 million in 2023, then increased by 16.99% to $19.8 million in 2024, then fell by 24.37% to $15.0 million in 2025.
  • Its Research & Development was $15.0 million in Q3 2025, compared to $17.2 million in Q2 2025 and $15.8 million in Q1 2025.